Insights - GEN-011 Phase 1 is “Accruing” Patients. Data Q4 2021-Q1 2022Accrued patients have given consent to be part of the trial and are undergoing the procedures … Continue Reading
Premium: Read NowInsights - Yesterday, Novavax (NVAX) announced a Memorandum of Understanding (MoU) to supply 1.1 billion doses to COVAX, a worldwide network designed to share access to COVID vaccines globally. … Continue Reading
Premium: Read NowInsights - Gene therapy companies were down big yesterday after bluebird bio (BLUE) announced that they will temporarily suspend their sickle cell disease programs. bluebird bio was down 37% … Continue Reading
Premium: Read NowInsights - Affimed (AFMD) announced a collaboration with Roche to study AFM24 in combination with Roche’s Tecentriq, a PD-L1 checkpoint inhibitor, in solid tumors. As per the agreement, Affimed … Continue Reading
Premium: Read NowInsights - Novavax is up 40% since we bought in the $200/share range less than a week ago. The thesis was that Novavax was better positioned than … Continue Reading
Premium: Read NowInsights - This morning, Concert Pharma (CNCE) announced that their schizophrenia candidate failed in Phase 2. CTP-692 did not achieve primary or secondary endpoints assessing positive and negative syndrome … Continue Reading
Premium: Read NowInsights - Yesterday, Novavax’s (NVAX) vaccine demonstrated 95.6% efficacy against the original COVID strain. This was the best result yet, edging out Moderna and Pfizer, who came in at … Continue Reading
Premium: Read Now
